Skip to the content
  • Suomeksi
  • About us
    • > Our role
    • > BoD and management
  • For pharma sector
    • > Research archive
  • Newsfeed
  • Contacts
  • Suomeksi

News
30.11.2021

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

coronavirus, Covid-19

A randomized, placebo-controlled phase 2–3 trial examined the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in 5-to-11-year-old children.

2,268 children were randomly assigned to receive two injections, 21 days apart, of either the BNT162b2 vaccine (at a dose level of 10 μg, selected during phase 1) or placebo. Outcomes included immunogenicity, adverse events, and efficacy against confirmed Covid-19.

Read the original article, as published on November 9, 2021 in the New England Journal of Medicine.

read the article

  • About us
    • Our role
    • BoD and management
  • For pharma sector
    • Research archive
  • Newsfeed
  • Contacts

FVR - Finnish Vaccine Research
Peltokatu 26, 33100 Tampere, Finland
info@fvr.fi Business ID FI32566594

  • About cookies

© Copyrights 2022 FVR – Finnish Vaccine Research